$289.12 Million in Sales Expected for Evolent Health, Inc. (NYSE:EVH) This Quarter

Brokerages expect Evolent Health, Inc. (NYSE:EVHGet Rating) to report sales of $289.12 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Evolent Health’s earnings. The highest sales estimate is $291.83 million and the lowest is $286.40 million. Evolent Health posted sales of $215.07 million during the same quarter last year, which suggests a positive year over year growth rate of 34.4%. The company is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Evolent Health will report full-year sales of $1.16 billion for the current fiscal year, with estimates ranging from $1.15 billion to $1.17 billion. For the next fiscal year, analysts anticipate that the firm will post sales of $1.37 billion, with estimates ranging from $1.33 billion to $1.40 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Evolent Health.

Evolent Health (NYSE:EVHGet Rating) last issued its quarterly earnings results on Wednesday, February 23rd. The technology company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.08. Evolent Health had a negative return on equity of 2.43% and a negative net margin of 4.14%. The company had revenue of $248.36 million for the quarter, compared to analyst estimates of $236.36 million. During the same quarter in the prior year, the company posted ($0.06) EPS.

A number of research analysts have weighed in on the company. Zacks Investment Research lowered Evolent Health from a “buy” rating to a “hold” rating in a research note on Wednesday, March 2nd. Guggenheim began coverage on Evolent Health in a research report on Tuesday, March 29th. They issued a “buy” rating and a $43.00 target price on the stock. BTIG Research boosted their price target on Evolent Health from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, March 25th. StockNews.com began coverage on Evolent Health in a report on Thursday, March 31st. They issued a “hold” rating on the stock. Finally, Piper Sandler reduced their price objective on Evolent Health from $36.00 to $32.00 in a research note on Thursday, February 24th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $38.67.

In related news, Director Frank J. Williams sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 18th. The stock was sold at an average price of $24.30, for a total transaction of $486,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Steve Tutewohl sold 1,707 shares of the business’s stock in a transaction that occurred on Thursday, February 3rd. The stock was sold at an average price of $22.85, for a total value of $39,004.95. The disclosure for this sale can be found here. Insiders sold a total of 55,326 shares of company stock worth $1,347,218 over the last ninety days. Corporate insiders own 4.20% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Vigilant Capital Management LLC acquired a new position in shares of Evolent Health in the 1st quarter valued at approximately $32,000. Manchester Capital Management LLC bought a new stake in shares of Evolent Health in the 3rd quarter valued at approximately $32,000. Point72 Hong Kong Ltd bought a new stake in shares of Evolent Health in the 4th quarter valued at approximately $72,000. O Shaughnessy Asset Management LLC increased its holdings in shares of Evolent Health by 444.9% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 3,226 shares of the technology company’s stock valued at $100,000 after acquiring an additional 2,634 shares during the last quarter. Finally, Advisor Group Holdings Inc. increased its holdings in shares of Evolent Health by 38.9% in the 4th quarter. Advisor Group Holdings Inc. now owns 4,055 shares of the technology company’s stock valued at $113,000 after acquiring an additional 1,135 shares during the last quarter.

Shares of Evolent Health stock traded down $0.67 during trading hours on Tuesday, reaching $30.33. 519,423 shares of the company’s stock were exchanged, compared to its average volume of 732,686. Evolent Health has a 52-week low of $17.62 and a 52-week high of $34.60. The company has a fifty day moving average of $28.31 and a 200-day moving average of $27.67. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.31.

Evolent Health Company Profile (Get Rating)

Evolent Health, Inc, a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management.

Featured Articles

Get a free copy of the Zacks research report on Evolent Health (EVH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.